Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Ura T, Hironaka S, Tsubosa Y, Mizusawa J, Kato K, Tsushima T, Fushiki K, Chin K, Tomori A, Okuno T, Matsushita H, Kojima T, Doki Y, Kusaba H, Fujitani K, Seki S, Kitagawa Y. Ura T, et al. Among authors: mizusawa j. Esophagus. 2023 Apr;20(2):272-280. doi: 10.1007/s10388-022-00968-9. Epub 2022 Nov 22. Esophagus. 2023. PMID: 36427158 Clinical Trial.
Negative impact of intraoperative blood loss on long-term outcome after curative gastrectomy for advanced gastric cancer: exploratory analysis of the JCOG1001 phase III trial.
Misawa K, Kurokawa Y, Mizusawa J, Takiguchi S, Doki Y, Makino S, Choda Y, Takeno A, Tokunaga M, Sano T, Sasako M, Yoshikawa T, Terashima M; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Misawa K, et al. Among authors: mizusawa j. Gastric Cancer. 2022 Mar;25(2):459-467. doi: 10.1007/s10120-021-01266-6. Epub 2021 Nov 19. Gastric Cancer. 2022. PMID: 34797440 Clinical Trial.
Recurrence patterns after curative gastrectomy for pStage II/III gastric cancer: Exploratory analysis of the randomized controlled JCOG1001 trial.
Toriumi T, Terashima M, Mizusawa J, Sato Y, Kurokawa Y, Takiguchi S, Doki Y, Shinohara H, Teshima S, Yasuda T, Ito S, Yoshikawa T, Sano T, Sasako M. Toriumi T, et al. Among authors: mizusawa j. Eur J Surg Oncol. 2023 Apr;49(4):838-844. doi: 10.1016/j.ejso.2022.11.093. Epub 2022 Nov 16. Eur J Surg Oncol. 2023. PMID: 36424261 Clinical Trial.
Assessment of heterogeneity according to hospital or medical experience factors in outcomes of chemotherapy for advanced biliary tract cancer: a post-hoc analysis of JCOG1113.
Fukushi K, Imaoka H, Ikeda M, Mizusawa J, Morizane C, Okusaka T, Kobayashi S, Sasahira N, Shimizu S, Yamazaki K, Okano N, Miwa H, Hara K, Satoi S, Sano K, Sakai K, Sugimoto R, Nakamura K, Terashima T, Ozaka M, Ueno M; JCOG Hepatobiliary and Pancreatic Oncology Group. Fukushi K, et al. Among authors: mizusawa j. Jpn J Clin Oncol. 2025 Jan 8:hyae188. doi: 10.1093/jjco/hyae188. Online ahead of print. Jpn J Clin Oncol. 2025. PMID: 39775866
Utility of circulating tumour DNA for prognosis and prediction of therapeutic effect in locally recurrent rectal cancer: study protocol for a multi-institutional, prospective observational study (JCOG1801A1, CAP-LR study).
Hashimoto T, Tsukada Y, Ito M, Kanato K, Mizusawa J, Fukuda H, Tsukamoto S, Takashima A, Kanemitsu Y. Hashimoto T, et al. Among authors: mizusawa j. BMJ Open. 2023 Aug 16;13(8):e073217. doi: 10.1136/bmjopen-2023-073217. BMJ Open. 2023. PMID: 37586869 Free PMC article.
Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy.
Ishiki H, Kikawa Y, Terada M, Mizusawa J, Honda M, Iwatani T, Mizutani T, Mori K, Nakamura N, Miyaji T, Yamaguchi T, Ando M, Nakamura K, Fukuda H, Kiyota N; PRO/QOL research Committee of Japan Clinical Oncology Group. Ishiki H, et al. Among authors: mizusawa j. Jpn J Clin Oncol. 2023 Mar 7;53(3):195-202. doi: 10.1093/jjco/hyad007. Jpn J Clin Oncol. 2023. PMID: 36702740 Free PMC article.
Randomized controlled phase III study comparing chemotherapy alone versus conversion surgery after a remarkable response to chemotherapy in patients with initially unresectable cStage IVB or pStage IV gastric cancer (JCOG2301, Conversion study).
Kita R, Yasufuku I, Takahashi N, Mizusawa J, Sano Y, Fukuda H, Kurokawa Y, Boku N, Terashima M, Yoshikawa T; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Kita R, et al. Among authors: mizusawa j. Jpn J Clin Oncol. 2024 Dec 18:hyae174. doi: 10.1093/jjco/hyae174. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39690810
Sex differences in toxicities and survival outcomes among Japanese patients with Stage III colorectal cancer receiving adjuvant fluoropyrimidine monotherapy: A pooled analysis of 4 randomized controlled trials (JCOG2310A).
Hirano H, Kataoka K, Yamaguchi T, Wagner AD, Shimada Y, Inomata M, Hamaguchi T, Takii Y, Mizusawa J, Sano Y, Shiomi A, Shiozawa M, Ohue M, Adachi T, Ueno H, Ikeda S, Komori K, Tsukamoto S, Takashima A, Kanemitsu Y. Hirano H, et al. Among authors: mizusawa j. Eur J Cancer. 2025 Jan;214:115139. doi: 10.1016/j.ejca.2024.115139. Epub 2024 Nov 19. Eur J Cancer. 2025. PMID: 39579641
191 results